SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Erasca, Inc. (ERAS) News

Follow Erasca, Inc. (ERAS) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 26 public stories across 12 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol ERAS Asset equity Sector Markets 90 days 6 Last 13.6 Updated Nov 04, 2026, 12:00 PM UTC Open live news feed Open ERAS chart & news
M Erasca Q3'26 Results Scheduled for Nov. 11 Erasca is scheduled to report Q3'26 results on November 11; revenue is estimated at 0 USD and EPS at (0.13) USD. The report time is not specified. EQUITY | Nov 04, 2026, 12:00 PM UTC L Erasca to present updated ERAS-0015 clinical data at EORTC-NCI-AACR symposium Erasca said it will deliver an oral presentation on updated ERAS-0015 monotherapy clinical data, covering additional patients and longer follow-up from AURORAS-1 Phase 1. It also plans a poster on nonclinical combination MACRO | Sep 10, 2026, 12:04 PM UTC L ERAS - Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium ERAS - Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium EQUITY | Sep 10, 2026, 12:02 PM UTC L Erasca to present at Morgan Stanley 24th Global Healthcare Conference Erasca, Inc. announced its participation in the Morgan Stanley 24th Annual Global Healthcare Conference. EQUITY | Sep 08, 2026, 11:08 AM UTC L ERAS - Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference ERAS - Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference EQUITY | Sep 08, 2026, 11:00 AM UTC M Erasca wins FDA Fast Track for ERAS-0015 in pancreatic cancer Erasca says the FDA granted Fast Track designation to its Pan-RAS molecular glue ERAS-0015 for patients with metastatic pancreatic adenocarcinoma. REGULATION | Aug 24, 2026, 12:00 PM UTC L Erasca Q2 EPS $(0.14) Misses $(0.11) Estimate Erasca (NASDAQ: ERAS ) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.11) by 27.27 percent. This is a 16.67 percent decrease over losses of $(0.12) per share from the sa EARNINGS | Aug 11, 2026, 08:39 PM UTC L ERAS - Erasca Reports Second Quarter 2026 Business Updates and Financial Results ERAS - Erasca Reports Second Quarter 2026 Business Updates and Financial Results EQUITY | Aug 11, 2026, 08:01 PM UTC H Erasca Sued for Securities Law Violations Erasca faces securities law violations lawsuit REGULATION | Jul 31, 2026, 06:58 AM UTC L ERAS PT raised from $21 to $24, maintains Buy @ JEFF ERAS PT raised from $21 to $24, maintains Buy @ JEFF EQUITY | Jul 15, 2026, 11:01 AM UTC L ERAS data update incrementally positive; registrational strategy taking shape @ GSCO ERAS data update incrementally positive; registrational strategy taking shape @ GSCO EQUITY | Jul 14, 2026, 01:00 PM UTC L Deal priced today • ERAS 31.4M share Spot Secondary, priced at $17.50, by JPMC, MSCO, JEFF & Evercore Deals to be priced today • QTTB $200M Deal priced today • ERAS 31.4M share Spot Secondary, priced at $17.50, by JPMC, MSCO, JEFF & Evercore Deals to be priced today • QTTB $200M Secondary announced last night, shares & pricing TBD, by MSCO, JEFF, Cantor, OPC REGULATION | Jul 14, 2026, 12:15 PM UTC L ERAS Erasca $500M Spot Secondary priced at $17.50; shares -1.5% premarket ERAS Erasca $500M Spot Secondary priced at $17.50; shares -1.5% premarket EQUITY | Jul 14, 2026, 10:47 AM UTC H Closing Bell Movers: Trex up 6% after positive Q2 pre-announcement Fast-unraveling ceasefire between Iran and U.S. amid continued dispute over the control of transit through the Strait of Hormuz has reverberated across the asset classes in a predictable fashion on Monday. WTI Crude Oil CENTRAL_BANK | Jul 13, 2026, 11:42 PM UTC L ERAS Erasca announces proposed public offering of $500M of common stock (more) ERAS Erasca announces proposed public offering of $500M of common stock (more) EQUITY | Jul 13, 2026, 08:19 PM UTC L ERAS -7.25% after study update, offering announced ERAS -7.25% after study update, offering announced EQUITY | Jul 13, 2026, 08:18 PM UTC L ERAS Erasca Inc: files for mixed shelf offering, size not disclosed - filing ERAS Erasca Inc: files for mixed shelf offering, size not disclosed - filing EQUITY | Jul 13, 2026, 08:16 PM UTC L ERAS Erasca - plans registration-enabling lung cancer trial in h1 2027; phase 3 pancreatic cancer trial in 2027 ERAS Erasca - plans registration-enabling lung cancer trial in h1 2027; phase 3 pancreatic cancer trial in 2027 EQUITY | Jul 13, 2026, 08:02 PM UTC L ERAS Erasca Inc: additional eras-0015 monotherapy and combination data expected h1 2027 ERAS Erasca Inc: additional eras-0015 monotherapy and combination data expected h1 2027 EQUITY | Jul 13, 2026, 08:02 PM UTC L ERAS Erasca announces updated preliminary phase 1 data and registration-enabling plans for potentially best-in-class pan-ras Molecular glue ERAS Erasca announces updated preliminary phase 1 data and registration-enabling plans for potentially best-in-class pan-ras Molecular glue eras-0015 in kras-mutant solid tumors EQUITY | Jul 13, 2026, 08:01 PM UTC L ERAS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Erasca, Inc. Shareholders Have Opportunity to Lead Class Action Law NEW YORK CITY, NY / / July 5, 2026 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-ri EQUITY | Jul 05, 2026, 11:00 AM UTC L ERAS INVESTOR REMINDER: Erasca, Inc. Investors Have Until August 10, 2026 to Seek Lead Plaintiff Role If you have suffered a loss on your EQUITY | Jul 04, 2026, 12:00 AM UTC L Securities Fraud Class Action Filed Against Erasca, Inc. (ERAS) - Levi & Korsinsky Reminds Investors of August 10, 2026 NEW YORK, NY / / July 3, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise EQUITY | Jul 03, 2026, 06:40 PM UTC L Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss -- HBSS SAN FRANCISCO, July 03, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ: ERAS) faces a sec EQUITY | Jul 03, 2026, 06:19 PM UTC L Pomerantz LLP Calls Attention to Class Action Against Erasca, Inc. – ERAS NEW YORK CITY, NY / / July 3, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against EQUITY | Jul 03, 2026, 11:00 AM UTC L ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Erasca, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Acti NEW YORK CITY, NY / / July 2, 2026 / WHY: Rosen Law Firm, a global investor rights law firm, re EQUITY | Jul 03, 2026, 01:45 AM UTC